Logo-bi
Bioimpacts. 2016;6(1): 49-67. doi: 10.15171/bi.2016.07
PMID: 27340624        PMCID: PMC4916551

Review

Advanced drug delivery and targeting technologies for the ocular diseases

Jaleh Barar 1 ORCID, Ayuob Aghanejad 1, Marziyeh Fathi 1, Yadollah Omidi 1 * ORCID

Cited by CrossRef: 92

1- Cañadas-Enrich C, Abrego G, Alvarado H, Calpena-Campmany A, Boix-Montañes A. Pranoprofen quantification in ex vivo corneal and scleral permeation samples: Analytical validation. Journal of Pharmaceutical and Biomedical Analysis. 2018;160:109 [Crossref]
2- Adrianto M, Annuryanti F, Wilson C, Sheshala R, Thakur R. In vitro dissolution testing models of ocular implants for posterior segment drug delivery. Drug Deliv and Transl Res. 2022;12(6):1355 [Crossref]
3- Sharif N. Glaucomatous optic neuropathy treatment options: the promise of novel therapeutics, techniques and tools to help preserve vision. Neural Regen Res. 2018;13(7):1145 [Crossref]
4- Zangabad P, Mirkiani S, Shahsavari S, Masoudi B, Masroor M, Hamed H, Jafari Z, Taghipour Y, Hashemi H, Karimi M, Hamblin M. Stimulus-responsive liposomes as smart nanoplatforms for drug delivery applications. 2018;7(1):95 [Crossref]
5- Bello M, Yang Y, Wang C, Wu L, Zhou P, Ding H, Ge X, Guo T, Wei L, Zhang J. Facile Synthesis and Size Control of 2D Cyclodextrin‐Based Metal–Organic Frameworks Nanosheet for Topical Drug Delivery. Part & Part Syst Charact. 2020;37(11) [Crossref]
6- Jiang K, Chen J, Tai L, Liu C, Chen X, Wei G, Lu W, Pan W. Inhibition of post-trabeculectomy fibrosis via topically instilled antisense oligonucleotide complexes co-loaded with fluorouracil. Acta Pharmaceutica Sinica B. 2020;10(9):1754 [Crossref]
7- Habot‐Wilner Z, Noronha G, Wykoff C. Suprachoroidally injected pharmacological agents for the treatment of chorio‐retinal diseases: a targeted approach. Acta Ophthalmologica. 2019;97(5):460 [Crossref]
8- Safary A, Akbarzadeh Khiavi M, Mousavi R, Barar J, Rafi M. Enzyme replacement therapies: what is the best option?. Bioimpacts. 2018;8(3):153 [Crossref]
9- Prieto E, Cardiel M, Vispe E, Idoipe M, Garcia-Martin E, Fraile J, Polo V, Mayoral J, Pablo L, Rodrigo M. Dexamethasone delivery to the ocular posterior segment by sustained-release Laponite formulation. Biomed Mater. 2020;15(6):065021 [Crossref]
10- Jemni-Damer N, Guedan-Duran A, Fuentes-Andion M, Serrano-Bengoechea N, Alfageme-Lopez N, Armada-Maresca F, Guinea G, Perez-Rigueiro J, Rojo F, Gonzalez-Nieto D, Kaplan D, Panetsos F. Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part II: Cell and Tissue Engineering Therapies. Front Bioeng Biotechnol. 2020;8 [Crossref]
11- Bessone C, Akhlaghi S, Tártara L, Quinteros D, Loh W, Allemandi D. Latanoprost-loaded phytantriol cubosomes for the treatment of glaucoma. European Journal of Pharmaceutical Sciences. 2021;160:105748 [Crossref]
12- Zhang J, Liu Z, Tao C, Lin X, Zhang M, Zeng L, Chen X, Song H. Cationic nanoemulsions with prolonged retention time as promising carriers for ophthalmic delivery of tacrolimus. European Journal of Pharmaceutical Sciences. 2020;144:105229 [Crossref]
13- Sadasivam R, Packirisamy G, Goswami M. Biocompatible soft hydrogel lens as topical implants for diabetic retinopathy. Materials Letters. 2022;318:132174 [Crossref]
14- Liu P, Wang F, Song Y, Wang M, Zhang X. Current situation and progress of drugs for reducing intraocular pressure. Therapeutic Advances in Chronic Disease. 2022;13:204062232211403 [Crossref]
15- Maharjan P, Cho K, Maharjan A, Shin M, Moon C, Min K. Pharmaceutical challenges and perspectives in developing ophthalmic drug formulations. J Pharm Investig. 2019;49(2):215 [Crossref]
16- Gote V, Ansong M, Pal D. Prodrugs and nanomicelles to overcome ocular barriers for drug penetration. Expert Opinion on Drug Metabolism & Toxicology. 2020;16(10):885 [Crossref]
17- Wang J, Fan W, Liu B, Pu N, Wu H, Xue R, Li S, Song Z, Tao Y. Encapsulated cell technology: Delivering cytokines to treat posterior ocular diseases. Pharmacological Research. 2024;203:107159 [Crossref]
18- Naftali Ben Haim L, Moisseiev E. Drug Delivery via the Suprachoroidal Space for the Treatment of Retinal Diseases. Pharmaceutics. 2021;13(7):967 [Crossref]
19- Busto-Iglesias M, Rodríguez-Martínez L, Rodríguez-Fernández C, González-López J, González-Barcia M, de Domingo B, Rodríguez-Rodríguez L, Fernández-Ferreiro A, Mondelo-García C. Perspectives of Therapeutic Drug Monitoring of Biological Agents in Non-Infectious Uveitis Treatment: A Review. Pharmaceutics. 2023;15(3):766 [Crossref]
20- Boddu S, Acharya D, Hala V, Jani H, Pande S, Patel C, Shahwan M, Jwala R, Ranch K. An Update on Strategies to Deliver Protein and Peptide Drugs to the Eye. ACS Omega. 2023;8(39):35470 [Crossref]
21- Sherwin J, Ratnarajan G, Elahi B, Bilkiewicz‐Pawelec A, Salmon J. Effect of a punctal plug on ocular surface disease in patients using topical prostaglandin analogues: a randomized controlled trial. Clinical Exper Ophthalmology. 2018;46(8):888 [Crossref]
22- Ghanavi M, Khoshandam A, Aslzad S, Fathi M, Barzegari A, Dalir Abdolahinia E, Adibkia K, Barar J, Omidi Y. Injectable thermosensitive PEG-g-chitosan hydrogel for ocular delivery of vancomycin and prednisolone. Journal of Drug Delivery Science and Technology. 2023;83:104385 [Crossref]
23- Bisht R, Jaiswal J, Rupenthal I. Nanoparticle-loaded biodegradable light-responsive in situ forming injectable implants for effective peptide delivery to the posterior segment of the eye. Medical Hypotheses. 2017;103:5 [Crossref]
24- Choudhari M, Nayak K, Nagai N, Nakazawa Y, Khunt D, Misra M. Role of mucoadhesive agent in ocular delivery of ganciclovir microemulsion: cytotoxicity evaluation in vitro and ex vivo. Int Ophthalmol. 2022;43(4):1153 [Crossref]
25- Zhang J, Jiao J, Niu M, Gao X, Zhang G, Yu H, Yang X, Liu L. Ten Years of Knowledge of Nano-Carrier Based Drug Delivery Systems in Ophthalmology: Current Evidence, Challenges, and Future Prospective. IJN. 2021;Volume 16:6497 [Crossref]
26- Thng Z, Bromeo A, Mohammadi S, Khatri A, Tran A, Akhavanrezayat A, T.T. Than N, Nguyen K, Yoo W, Mobasserian A, Or C, Nguyen Q. Recent advances in uveitis therapy: focus on selected phase 2 and 3 clinical trials. Expert Opinion on Emerging Drugs. 2023;28(4):297 [Crossref]
27- Zhao L, Peng M, Lin W, Tan Q, Khan M, Lin D.

Efficacy of Sub-Tenon Micro-Perfusion of Cyclophosphamide in Rabbits with Severe Ocular Inflammation

. DDDT. 2020;Volume 14:3407 [Crossref]
28- Nagai N, Daigaku R, Motoyama R, Kaji H, Abe T. Release of ranibizumab using a porous poly(dimethylsiloxane) capsule suppressed laser-induced choroidal neovascularization via the transscleral route. J Mater Sci: Mater Med. 2022;34(1) [Crossref]
29- Awwad S, Mohamed Ahmed A, Sharma G, Heng J, Khaw P, Brocchini S, Lockwood A. Principles of pharmacology in the eye. British J Pharmacology. 2017;174(23):4205 [Crossref]
30- Wu B, Li M, Li K, Hong W, Lv Q, Li Y, Xie S, Han J, Tian B. Cell penetrating peptide TAT-functionalized liposomes for efficient ophthalmic delivery of flurbiprofen: Penetration and its underlying mechanism, retention, anti-inflammation and biocompatibility. International Journal of Pharmaceutics. 2021;598:120405 [Crossref]
31- Duskey J, da Ros F, Ottonelli I, Zambelli B, Vandelli M, Tosi G, Ruozi B. Enzyme Stability in Nanoparticle Preparations Part 1: Bovine Serum Albumin Improves Enzyme Function. Molecules. 2020;25(20):4593 [Crossref]
32- Lorenzo-Veiga B, Alvarez-Lorenzo C, Loftsson T, Sigurdsson H. Age-related ocular conditions: Current treatments and role of cyclodextrin-based nanotherapies. International Journal of Pharmaceutics. 2021;603:120707 [Crossref]
33- Mohsen A. Cationic Polymeric Nanoparticles for Improved Ocular Delivery and Antimycotic Activity of Terconazole. Journal of Pharmaceutical Sciences. 2022;111(2):458 [Crossref]
34- Balguri S, Adelli G, Janga K, Bhagav P, Majumdar S. Ocular disposition of ciprofloxacin from topical, PEGylated nanostructured lipid carriers: Effect of molecular weight and density of poly (ethylene) glycol. International Journal of Pharmaceutics. 2017;529(1-2):32 [Crossref]
35- Cabrera F, Wang D, Reddy K, Acharya G, Shin C. Challenges and opportunities for drug delivery to the posterior of the eye. Drug Discovery Today. 2019;24(8):1679 [Crossref]
36- Lynch C, Kondiah P, Choonara Y, du Toit L, Ally N, Pillay V. Advances in Biodegradable Nano-Sized Polymer-Based Ocular Drug Delivery. Polymers. 2019;11(8):1371 [Crossref]
37- Chatterjee S, Upadhyay P, Mishra M, M. S, Akshara M, N. K, Zaidi Z, Iqbal S, Misra S. Advances in chemistry and composition of soft materials for drug releasing contact lenses. RSC Adv. 2020;10(60):36751 [Crossref]
38- Nayak K, Misra M. A review on recent drug delivery systems for posterior segment of eye. Biomedicine & Pharmacotherapy. 2018;107:1564 [Crossref]
39- Awwad S, Al‐Shohani A, Khaw P, Brocchini S. Comparative Study of In Situ Loaded Antibody and PEG‐Fab NIPAAM Gels. Macromolecular Bioscience. 2018;18(2) [Crossref]
40- Qi Q, Wei Y, Zhang X, Guan J, Mao S. Challenges and strategies for ocular posterior diseases therapy via non-invasive advanced drug delivery. Journal of Controlled Release. 2023;361:191 [Crossref]
41- Ismail O, Henry C. An Update on Suprachoroidal Corticosteroid Injections in the Management of Macular Edema. Curr Ophthalmol Rep. 2022;10(3):91 [Crossref]
42- Poustforoosh A, Nematollahi M, Hashemipour H, Pardakhty A. Recent advances in Bio-conjugated nanocarriers for crossing the Blood-Brain Barrier in (pre-)clinical studies with an emphasis on vesicles. Journal of Controlled Release. 2022;343:777 [Crossref]
43- Cosert K, Kim S, Jalilian I, Chang M, Gates B, Pinkerton K, Van Winkle L, Raghunathan V, Leonard B, Thomasy S. Metallic Engineered Nanomaterials and Ocular Toxicity: A Current Perspective. Pharmaceutics. 2022;14(5):981 [Crossref]
44- Fu L, Kwok S, Chan Y, Ming Lai J, Pan W, Nie L, Shih K. Therapeutic Strategies for Attenuation of Retinal Ganglion Cell Injury in Optic Neuropathies: Concepts in Translational Research and Therapeutic Implications. BioMed Research International. 2019;2019:1 [Crossref]
45- Irimia T, Ghica M, Popa L, Anuţa V, Arsene A, Dinu-Pîrvu C. Strategies for Improving Ocular Drug Bioavailability and Corneal Wound Healing with Chitosan-Based Delivery Systems. Polymers. 2018;10(11):1221 [Crossref]
46- Yousry C, Zikry P, Basalious E, El-Gazayerly O. Self-nanoemulsifying System Optimization for Higher Terconazole Solubilization and Non-Irritant Ocular Administration. Adv Pharm Bull. 2020;10(3):389 [Crossref]
47- Jin S, Hwang S. Ocular delivery systems for the administration of antibody therapeutics. Journal of Pharmaceutical Investigation. 2017;47(5):373 [Crossref]
48- Fathi M, Safary A, Barar J. Therapeutic impacts of enzyme-responsive smart nanobiosystems. Bioimpacts. 2019;10(1):1 [Crossref]
49- Biswas A, Choudhury A, Bisen A, Agrawal S, Sanap S, Verma S, Mishra A, Kumar S, Bhatta R. Trends in Formulation Approaches for Sustained Drug Delivery to the Posterior Segment of the Eye. AAPS PharmSciTech. 2023;24(8) [Crossref]
50- Garg V, Suri R, Jain G, Kohli K. Proglycosomes: A novel nano-vesicle for ocular delivery of tacrolimus. Colloids and Surfaces B: Biointerfaces. 2017;157:40 [Crossref]
51- Jung J, Chae J, Prausnitz M. Targeting drug delivery within the suprachoroidal space. Drug Discovery Today. 2019;24(8):1654 [Crossref]
52- Bhatt M, Shende P. Modulated approaches for strategic transportation of proteins and peptides via ocular route. Journal of Drug Delivery Science and Technology. 2021;66:102835 [Crossref]
53- Kubo Y, Akanuma S, Hosoya K. Recent advances in drug and nutrient transport across the blood-retinal barrier. Expert Opinion on Drug Metabolism & Toxicology. 2018;14(5):513 [Crossref]
54- Safary A, Akbarzadeh Khiavi M, Omidi Y, Rafi M. Targeted enzyme delivery systems in lysosomal disorders: an innovative form of therapy for mucopolysaccharidosis. Cell Mol Life Sci. 2019;76(17):3363 [Crossref]
55- Adısanoğlu P, Özgüney I. Development and Characterization of Thermosensitive and Bioadhesive Ophthalmic Formulations Containing Flurbiprofen Solid Dispersions. Gels. 2024;10(4):267 [Crossref]
56- Emami A, Tepper J, Short B, Yaksh T, Bendele A, Ramani T, Cisternas A, Chang J, Mellon R. Toxicology Evaluation of Drugs Administered via Uncommon Routes: Intranasal, Intraocular, Intrathecal/Intraspinal, and Intra-Articular. Int J Toxicol. 2018;37(1):4 [Crossref]
57- Alambiaga-Caravaca A, Calatayud-Pascual M, Rodilla V, Concheiro A, López-Castellano A, Alvarez-Lorenzo C. Micelles of Progesterone for Topical Eye Administration: Interspecies and Intertissues Differences in Ex Vivo Ocular Permeability. Pharmaceutics. 2020;12(8):702 [Crossref]
58- Shastri D, Silva A, Almeida H. Ocular Delivery of Therapeutic Proteins: A Review. Pharmaceutics. 2023;15(1):205 [Crossref]
59- Mora-Pereira M, Abarca E, Duran S, Ravis W, McMullen R, Fischer B, Lee Y, Wooldridge A. Sustained-release voriconazole-thermogel for subconjunctival injection in horses: ocular toxicity and in-vivo studies. BMC Vet Res. 2020;16(1) [Crossref]
60- Nagai N, Nezhad Z, Daigaku R, Saijo S, Song Y, Terata K, Hoshi A, Nishizawa M, Nakazawa T, Kaji H, Abe T. Transscleral sustained ranibizumab delivery using an episcleral implantable device: Suppression of laser-induced choroidal neovascularization in rats. International Journal of Pharmaceutics. 2019;567:118458 [Crossref]
61- Kopp F, Eickner T, Polei S, Falke K, Witt M, Grabow N, Stachs O, Guthoff R, Lindner T. Ultrahigh field MR imaging of a subconjunctival anti-glaucoma drug delivery system in a rabbit model. Sci Rep. 2017;7(1) [Crossref]
62- Pietrucha-Dutczak M, Amadio M, Govoni S, Lewin-Kowalik J, Smedowski A. The Role of Endogenous Neuroprotective Mechanisms in the Prevention of Retinal Ganglion Cells Degeneration. Front Neurosci. 2018;12 [Crossref]
63- Wong C, Czarny B, Metselaar J, Ho C, Ng S, Barathi A, Storm G, Wong T. Evaluation of subconjunctival liposomal steroids for the treatment of experimental uveitis. Sci Rep. 2018;8(1) [Crossref]
64- Han H, Li S, Xu M, Zhong Y, Fan W, Xu J, Zhou T, Ji J, Ye J, Yao K. Polymer- and lipid-based nanocarriers for ocular drug delivery: Current status and future perspectives. Advanced Drug Delivery Reviews. 2023;196:114770 [Crossref]
65- Goswami M, Sadasivam R, Packirisamy G. Viability studies of hydrogel contact lens on a 3D printed platform as ocular drug delivery carrier for diabetic retinopathy. Materials Letters. 2023;333:133636 [Crossref]
66- Barar J, Rafi M, Pourseif M, Omidi Y. Blood-brain barrier transport machineries and targeted therapy of brain diseases. Bioimpacts. 2016;6(4):225 [Crossref]
67- Agrahari V, Agrahari V, Mandal A, Pal D, Mitra A. How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches. Expert Opinion on Drug Delivery. 2017;14(10):1145 [Crossref]
68- Pakzad Y, Fathi M, Omidi Y, Mozafari M, Zamanian A. Synthesis and characterization of timolol maleate-loaded quaternized chitosan-based thermosensitive hydrogel: A transparent topical ocular delivery system for the treatment of glaucoma. International Journal of Biological Macromolecules. 2020;159:117 [Crossref]
69- Omer S, Zelkó R. A Systematic Review of Drug-Loaded Electrospun Nanofiber-Based Ophthalmic Inserts. Pharmaceutics. 2021;13(10):1637 [Crossref]
70- Samiei M, Fathi M, Barar J, Fathi N, Amiryaghoubi N, Omidi Y. Bioactive hydrogel-based scaffolds for the regeneration of dental pulp tissue. Journal of Drug Delivery Science and Technology. 2021;64:102600 [Crossref]
71- Fan X, Jiang K, Geng F, Lu W, Wei G. Ocular therapies with biomacromolecules: From local injection to eyedrop and emerging noninvasive delivery strategies. Advanced Drug Delivery Reviews. 2023;197:114864 [Crossref]
72- Mukherjee S, Karati D, Singh S, Prajapati B. Chitosan-based Nanomedicine in the Management of Age-related Macular Degeneration: A Review. CNANOM. 2024;14(1):13 [Crossref]
73- Quarterman J, Geary S, Salem A. Evolution of drug-eluting biomedical implants for sustained drug delivery. European Journal of Pharmaceutics and Biopharmaceutics. 2021;159:21 [Crossref]
74- Qamar Z, Qizilbash F, Iqubal M, Ali A, Narang J, Ali J, Baboota S. Nano-Based Drug Delivery System: Recent Strategies for the Treatment of Ocular Disease and Future Perspective. DDF. 2020;13(4):246 [Crossref]
75- Chen C, Liu K, Xu Y, Zhang P, Suo Y, Lu Y, Zhang W, Su L, Gu Q, Wang H, Gu J, Li Z, Xu X. Anti-angiogenesis through noninvasive to minimally invasive intraocular delivery of the peptide CC12 identified by in vivo-directed evolution. Biomaterials. 2017;112:218 [Crossref]
76- Xu M, Li S. Nano-drug delivery system targeting tumor microenvironment: A prospective strategy for melanoma treatment. Cancer Letters. 2023;574:216397 [Crossref]
77- Hashida N, Nishida K. Recent advances and future prospects: Current status and challenges of the intraocular injection of drugs for vitreoretinal diseases. Advanced Drug Delivery Reviews. 2023;198:114870 [Crossref]
78- Polat H, Bozdağ Pehlivan S, Özkul C, Çalamak S, Öztürk N, Aytekin E, Fırat A, Ulubayram K, Kocabeyoğlu S, İrkeç M, Çalış S. Development of besifloxacin HCl loaded nanofibrous ocular inserts for the treatment of bacterial keratitis: In vitro, ex vivo and in vivo evaluation. International Journal of Pharmaceutics. 2020;585:119552 [Crossref]
79- Mandal A, Pal D, Agrahari V, Trinh H, Joseph M, Mitra A. Ocular delivery of proteins and peptides: Challenges and novel formulation approaches. Advanced Drug Delivery Reviews. 2018;126:67 [Crossref]

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge